2023
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentCost-Benefit AnalysisCost-Effectiveness AnalysisHumansTyphoid FeverTyphoid-Paratyphoid VaccinesVaccines, ConjugateConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitionsCost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity
Kostic AM, Leifer VP, Selzer F, Hunter DJ, Paltiel AD, Chen AF, Robinson MK, Neogi T, Collins JE, Messier SP, Edwards RR, Katz JN, Losina E. Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity. Arthritis Care & Research 2023, 75: 1752-1763. PMID: 36250415, PMCID: PMC10375659, DOI: 10.1002/acr.25044.Peer-Reviewed Original ResearchMeSH KeywordsArthroplasty, Replacement, KneeCost-Benefit AnalysisGastrectomyGastric BypassHumansObesityObesity, MorbidOsteoarthritis, KneeWeight LossConceptsLaparoscopic sleeve gastrectomyClass III obesityIncremental cost-effectiveness ratioTotal knee replacementQuality-adjusted life expectancyWeight loss interventionProbabilistic sensitivity analysesKnee replacementNonsurgical weight loss interventionsLong-term clinical benefitWeight lossKnee osteoarthritis patientsWeight loss strategiesHealth care sector perspectiveOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioWeight loss/Gastric bypassSleeve gastrectomyPrimary outcomeLoss interventionOsteoarthritis patientsClinical benefitHigher complications
2022
Cost‐effectiveness of hepatitis C virus test‐and‐treat and risk reduction strategies among men who have sex with men living with HIV in France
Castry M, Cousien A, Champenois K, Supervie V, Velter A, Ghosn J, Yazdanpanah Y, Paltiel A, Deuffic‐Burban S. Cost‐effectiveness of hepatitis C virus test‐and‐treat and risk reduction strategies among men who have sex with men living with HIV in France. Journal Of The International AIDS Society 2022, 25: e26035. PMID: 36451286, PMCID: PMC9712801, DOI: 10.1002/jia2.26035.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisFranceHepacivirusHepatitis CHIV InfectionsHomosexuality, MaleHumansMaleSexual and Gender MinoritiesConceptsHuman immunodeficiency virusIncremental cost-effectiveness ratioHigh-risk groupHepatitis C virusHCV screeningRisk reduction strategiesHCV infectionYearly screeningHepatitis C Virus TestRisk reductionHCV screening practicesNew HCV infectionsHigh-risk individualsRisk reduction interventionsCost-effectiveness ratioCost-effective dependingImmunodeficiency virusC virusScreening practicesLifetime horizonScreening frequencyVirus testReduction interventionsRisk behaviorsBehavioral interventionsDoes gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis
Bensen G, Rogers A, Leifer V, Edwards R, Neogi T, Kostic A, Paltiel A, Collins J, Hunter D, Katz J, Losina E. Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis. Osteoarthritis And Cartilage 2022, 31: 279-290. PMID: 36414225, PMCID: PMC9892279, DOI: 10.1016/j.joca.2022.07.013.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisCost-Effectiveness AnalysisGabapentinHumansNeuralgiaOsteoarthritis, KneeQuality-Adjusted Life YearsConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioKnee osteoarthritisUsual careNociplastic painCumulative quality-adjusted life yearsMore quality-adjusted life yearsNeuropathic pain syndromesDirect medical costsOsteoarthritis Policy ModelLifetime direct medical costsCost-effectiveness ratioCost-effectiveness analysisOA carePainDETECT questionnairePain syndromeEstimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study
Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, Thornhill T, Gonsalves G. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open 2022, 12: e061752. PMID: 36100306, PMCID: PMC9471205, DOI: 10.1136/bmjopen-2022-061752.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisCOVID-19COVID-19 VaccinesDeveloping CountriesHumansMRNA VaccinesRNA, MessengerRNA, ViralSARS-CoV-2VaccinationVaccines, SyntheticConceptsLow-income countriesIncome countriesDeath avertedHigh-income nationsStatistical lifeAvertable deathsIncome nationsCOVID-19 deathsReasonable investmentHigh costKey inputCountriesParameter estimatesAvertedCostSensitivity analysisUniversal vaccinationGlobal vaccinationMRNA COVID-19 vaccinationNationsInvestmentPrimary vaccine seriesLow vaccine effectivenessCOVID-19 vaccinationPublic dataCost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2022, 175: 479-489. PMID: 35099992, PMCID: PMC9087297, DOI: 10.7326/m21-1548.Peer-Reviewed Original ResearchConceptsCAB-LAHIV preexposure prophylaxisCost-effectiveness analysisPreexposure prophylaxisHigh riskNational InstituteIncremental cost-effectiveness ratioCost-effectiveness ratioBase-case analysisHealth care systemEunice KennedyInjectable cabotegravirPrEP retentionOral PrEPHIV PrEPHIV incidenceBlood InstituteDisoproxil fumarateNational HeartChild healthSide effectsTransgender womenInfectious diseasesPrEPQALY
2021
The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis.
Chen AT, Bronsther CI, Stanley EE, Paltiel AD, Sullivan JK, Collins JE, Neogi T, Katz JN, Losina E. The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2021, 174: 747-757. PMID: 33750190, PMCID: PMC8288249, DOI: 10.7326/m20-4722.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioBody mass indexTotal knee replacementKnee replacementCost-effectiveness analysisTKR recipientsKnee osteoarthritisMass indexEnd-stage knee osteoarthritisLong-term clinical benefitCost-effective strategyPreoperative pain levelNational InstituteOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioBase-case analysisProbabilistic sensitivity analysesMultiple comorbiditiesCost-effectiveness perspectivePain levelsComplication rateClinical benefitCardiovascular diseaseMedical costsClinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.
Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. Annals Of Internal Medicine 2021, 174: 803-810. PMID: 33683930, PMCID: PMC9317280, DOI: 10.7326/m21-0510.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Antigen testingHome testingSARS-CoV-2 antigen testingIncremental cost-effectiveness ratioSARS-CoV-2 transmissionCost-effectiveness ratioBase-case analysisRapid testingPrevention guidanceDeath avertedDisease progressionInpatient careCommunity transmissionOutcome estimatesTesting interventionsViral transmissionDisease controlInfectionNumber of personsCumulative infectionsNational containment strategyWarrants considerationU.S. populationDeathAdaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic
Yaesoubi R, Havumaki J, Chitwood MH, Menzies NA, Gonsalves G, Salomon JA, Paltiel AD, Cohen T. Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. Medical Decision Making 2021, 41: 386-392. PMID: 33504258, PMCID: PMC8084913, DOI: 10.1177/0272989x21990371.Peer-Reviewed Original ResearchConceptsAdaptive policiesClear decision rulesSocial costsEconomic costsPolicy makersPhysical distancing policiesDecision toolPolicyPhysical distancing interventionsDistancing policiesModel-based experimentsDecision rulesReal-time surveillance dataCostCOVID-19 pandemicMakersShorter overall durationMore complex modelsHealth benefitsComplex modelsPandemicCurrent pandemicCOVID-19BenefitsRules
2020
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis. Annals Of Internal Medicine 2020, 173: 507-508. PMID: 32926822, DOI: 10.7326/l20-0693.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAlanineCost-Benefit AnalysisEmtricitabineFamilyHIV InfectionsHumansPre-Exposure ProphylaxisTenofovirCost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States
Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, Paltiel AD, Weinstein MC, Wilson CM, Ciaranello AL. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases 2020, 73: e1927-e1935. PMID: 32730625, PMCID: PMC8492162, DOI: 10.1093/cid/ciaa1061.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHIV transmissionAge 15High-risk young menAdolescent Medicine Trials NetworkAntiretroviral therapy initiationIncremental cost-effectiveness ratioNew HIV infectionsLife expectancyYoung menCost-effectiveness ratioFrequent HIVCD4 countHIV screeningTherapy initiationHIV infectionClinical outcomesHIV incidenceClinical benefitFrequent screeningART costsHIVAge 30Trials NetworkYMSMAssessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States
Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. JAMA Network Open 2020, 3: e2016818. PMID: 32735339, PMCID: PMC7395236, DOI: 10.1001/jamanetworkopen.2020.16818.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSymptom-based screeningTrue-positive resultsCost-effectiveness analysisHypothetical cohortCumulative infectionsAsymptomatic SARS-CoV-2 infectionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Safe returnCoronavirus disease 2019 (COVID-19) pandemicSyndrome coronavirus 2Case fatality riskCOVID-19 infectionDisease 2019 pandemicResidential college campusCoronavirus 2Additional infectionsMAIN OUTCOMEBudget impactInfectionBehavioral interventionsCohortFall 2020 semesterComparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2020, 172: 583-590. PMID: 32150602, PMCID: PMC7217721, DOI: 10.7326/m19-3478.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioCost-effectiveness analysisFair priceCost-effectiveness ratioBase-case analysisJustifiable priceSocietal willingnessComparative pricingHealth care sectorPricesTime horizonEnd-stage renal diseaseCases of ESRDQALYDemand PrEPCare sectorEconomic savingsHIV preexposure prophylaxisSensitivity analysisCostPreexposure prophylaxisLife effectsHorizonPricingDiscount
2019
Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis
Morozova O, Crawford FW, Cohen T, Paltiel AD, Altice FL. Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction 2019, 115: 437-450. PMID: 31478285, PMCID: PMC7015766, DOI: 10.1111/add.14797.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderOAT coverageAgonist treatmentGross domestic productOpioid use initiationOpioid addiction epidemicOAT accessHIV epidemicUse disordersAddiction epidemicCapita gross domestic productPay thresholdsTreatment demandUse initiationAddiction treatmentIncremental costBaseline capacityTreatmentPotential peer effectsDomestic productTreatment spilloversEpidemicPeer effectsCoverage levelsA Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management
Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. Value In Health 2019, 22: 1102-1110. PMID: 31563252, PMCID: PMC7343670, DOI: 10.1016/j.jval.2019.05.004.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerObservational studyBreast cancerLow-risk early-stage breast cancerHormone receptor-positive early-stage breast cancerPredictive valueLow-risk womenProspective observational studyHigh-risk womenRetrospective observational studyBreast cancer managementQuality-adjusted life yearsCost-effectiveness findingsTraditional risk predictionAdjuvant chemotherapyChemotherapy useAlternative study designsOncotype DXCancer managementClinical utilityCurrent evidenceInsufficient evidenceLife yearsRoutine useStudy designRapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector
Lee DJ, Kumarasamy N, Resch SC, Sivaramakrishnan GN, Mayer KH, Tripathy S, Paltiel AD, Freedberg KA, Reddy KP. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector. PLOS ONE 2019, 14: e0218890. PMID: 31265470, PMCID: PMC6605662, DOI: 10.1371/journal.pone.0218890.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLife expectancySmear microscopyXpert MTB/RIFHIV-negative adultsPeripheral healthcare settingsMTB/RIFPrimary healthcare facilitiesSputum smear microscopyCost-effectiveness ratioCost-effectiveness analysisPresumptive tuberculosisTB diagnosisTB prevalenceTruenatMicroscopy centresXpertBudget impactRifampicin resistanceDiagnostic strategiesTuberculosisTB detectionHealthcare settingsDiagnostic sensitivityNovel molecular assayCost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDietCost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis
Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis. PLOS ONE 2019, 14: e0219068. PMID: 31247009, PMCID: PMC6597104, DOI: 10.1371/journal.pone.0219068.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioImmediate ARTImmediate ART initiationART initiationBudget impactLife expectancyImmediate antiretroviral therapy initiationDecrease HIV transmissionLate ART initiationModest budget impactAntiretroviral therapy initiationMedical resource useCost-effectiveness ratioCost-effectiveness analysisTherapy initiationHIV infectionHIV transmissionCôte d'IvoireART costsART efficacySTART trialCare budgetCD4CareOutcomesCost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The Lancet Infectious Diseases 2019, 19: 728-739. PMID: 31130329, PMCID: PMC6595249, DOI: 10.1016/s1473-3099(18)30804-1.Peer-Reviewed Original ResearchConceptsGross domestic productWTP valuesCountry's gross domestic productOptimal strategyCountry-specific willingnessAverage net benefitHealth economic evaluationsGAVI-eligible countriesTyphoid ViPay valueDomestic productVaccine priceWTP thresholdEconomic evaluationVaccine-related costsNet benefitMiddle-income countriesGavi supportVaccine AllianceRoutine immunisationHospital admissionCountriesTCV introductionDALYsTransmission dynamic modelThe Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India
Kazemian P, Costantini S, Kumarasamy N, Paltiel AD, Mayer KH, Chandhiok N, Walensky RP, Freedberg KA. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. Clinical Infectious Diseases 2019, 70: 633-642. PMID: 30921454, PMCID: PMC7319272, DOI: 10.1093/cid/ciz249.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCost-Benefit AnalysisHIVHIV InfectionsHIV TestingHomosexuality, MaleHumansIndiaMalePre-Exposure ProphylaxisSexual and Gender MinoritiesConceptsHIV testing strategiesPreexposure prophylaxisHIV incidenceCost-effective HIV prevention strategyHuman immunodeficiency virus (HIV) preexposure prophylaxisHuman immunodeficiency virus (HIV) epidemicQuarterly HIV testingHigh HIV incidenceHigh-risk groupHIV prevention strategiesIndia-specific dataWorld Health OrganizationIndian MSMRoutine HIVHIV testHIV testingTesting strategiesPWIDPrevention strategiesHIVMean incidenceGross domestic productPrEPMSMHealth Organization